Search
Bori Pharmaceutical, along with its subsidiary entities, has entered into a "Cooperative R&D Agreement" with CR Sanjiu, aiming to collaboratively advance the research and development, registration, production, and commercialization of BGM0504 injection within mainland China. BGM0504 injection, an independently developed Class 1 innovative drug by Bori Pharmaceutical, serves as a dual agonist for both GLP-1 and GIP receptors, offering a multitude of potential benefits such as blood sugar management, weight reduction, and treatment for non-alcoholic steatohepatitis (NASH). Currently, this promising medication is in the research and development phase and will not be available on the market until it successfully completes Phase III clinical trials and secures approval from the National Medical Products Administration.
-
C114 Communication Network -
Communication Home
